Jessica Most, MD
Pulmonary Disease · Philadelphia, PANPI 1073774857
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by AstraZeneca at 53.9% of the total. Reporting peaked in 2023 at $34,498 and has fallen 87.0% since, to $4,494 in 2024. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $519.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$35K
- GSK$14K
- Genentech USA, Inc.$7K
- Amgen$5K
- Astrazeneca AB$2K
- Sanofi$1K
- plus $226 from 4 others
Across 19 payments — averaging $15,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$297K
What the payments were for
- Consulting fees$25,88740%
- Speaking & faculty fees$33,42552%
- Travel & lodging$1,4032%
- Food & beverage$3,5606%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $34,717 |
| GSK | 42 | $14,247 |
| Genentech USA, Inc. | 11 | $7,261 |
| Amgen | 7 | $4,869 |
| Astrazeneca AB | 1 | $1,976 |
| Sanofi | 5 | $1,070 |
| Regeneron Healthcare Solutions, Inc. | 1 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Novartis | 3 | $42 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,365 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 55 | $307,406 |
| Dupixent PenDupilumab | 78 | $290,934 |
| TezspireTezepelumab-Ekko | 68 | $280,371 |
| NucalaMepolizumab | 27 | $247,294 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 182 | $194,843 |
| Dupixent SyringeDupilumab | 30 | $127,835 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $95,820 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $48,517 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $32,083 |
| Spiriva RespimatTiotropium Bromide | 47 | $27,685 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $17,963 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $13,863 |
| Advair DiskusFluticasone Propion/Salmeterol | 30 | $8,429 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $8,412 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $14,247 | $503,633320 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $34,717 | $342,750166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.